Affinity Asset Advisors LLC Lowers Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Affinity Asset Advisors LLC decreased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 69.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 159,614 shares of the company's stock after selling 365,386 shares during the period. Affinity Asset Advisors LLC owned approximately 0.20% of Viridian Therapeutics worth $3,060,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. XTX Topco Ltd bought a new stake in shares of Viridian Therapeutics in the fourth quarter valued at approximately $440,000. Barclays PLC raised its holdings in Viridian Therapeutics by 25.9% in the 4th quarter. Barclays PLC now owns 157,860 shares of the company's stock valued at $3,027,000 after acquiring an additional 32,463 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Viridian Therapeutics during the 4th quarter worth $6,015,000. Finally, Renaissance Technologies LLC increased its position in shares of Viridian Therapeutics by 522.8% in the fourth quarter. Renaissance Technologies LLC now owns 371,200 shares of the company's stock worth $7,116,000 after purchasing an additional 311,600 shares during the period.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN traded up $0.48 during trading hours on Friday, reaching $13.13. The company had a trading volume of 803,097 shares, compared to its average volume of 1,204,921. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -3.05 and a beta of 0.81. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm's 50 day moving average price is $14.55 and its 200-day moving average price is $18.62. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.24. The firm had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. On average, analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.